全文获取类型
收费全文 | 48453篇 |
免费 | 3895篇 |
国内免费 | 1491篇 |
专业分类
耳鼻咽喉 | 408篇 |
儿科学 | 939篇 |
妇产科学 | 415篇 |
基础医学 | 5392篇 |
口腔科学 | 2659篇 |
临床医学 | 3576篇 |
内科学 | 5582篇 |
皮肤病学 | 399篇 |
神经病学 | 1671篇 |
特种医学 | 2844篇 |
外国民族医学 | 6篇 |
外科学 | 13369篇 |
综合类 | 5716篇 |
现状与发展 | 3篇 |
一般理论 | 1篇 |
预防医学 | 3653篇 |
眼科学 | 502篇 |
药学 | 2845篇 |
15篇 | |
中国医学 | 1445篇 |
肿瘤学 | 2399篇 |
出版年
2024年 | 86篇 |
2023年 | 511篇 |
2022年 | 1215篇 |
2021年 | 1509篇 |
2020年 | 1263篇 |
2019年 | 1496篇 |
2018年 | 1539篇 |
2017年 | 1241篇 |
2016年 | 1460篇 |
2015年 | 1616篇 |
2014年 | 2723篇 |
2013年 | 3023篇 |
2012年 | 2446篇 |
2011年 | 2828篇 |
2010年 | 2347篇 |
2009年 | 2495篇 |
2008年 | 2488篇 |
2007年 | 2458篇 |
2006年 | 2336篇 |
2005年 | 2356篇 |
2004年 | 1971篇 |
2003年 | 1681篇 |
2002年 | 1292篇 |
2001年 | 1159篇 |
2000年 | 1099篇 |
1999年 | 913篇 |
1998年 | 745篇 |
1997年 | 755篇 |
1996年 | 596篇 |
1995年 | 573篇 |
1994年 | 484篇 |
1993年 | 437篇 |
1992年 | 401篇 |
1991年 | 333篇 |
1990年 | 296篇 |
1989年 | 242篇 |
1988年 | 247篇 |
1987年 | 202篇 |
1986年 | 197篇 |
1985年 | 336篇 |
1984年 | 354篇 |
1983年 | 246篇 |
1982年 | 305篇 |
1981年 | 268篇 |
1980年 | 242篇 |
1979年 | 225篇 |
1978年 | 175篇 |
1977年 | 142篇 |
1976年 | 125篇 |
1973年 | 83篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Fast and slow twitch muscle fibers have distinct contractile properties. Here we determined that membrane excitability also varies with fiber type. Na+ currents (INA) were studied with the loose-patch voltage clamp technique on 29 histochemically classified human intercostal skeletal muscle fibers at the endplate border and <200 μm from the endplate (extrajunctional). Fast and slow twitch fibers showed slow inactivation of endplate border and extrajunctional INA and had increased INA at the endplate border compared to extrajunctional membrane. The voltage dependencies of INA were similar on the endplate border and extrajunctional membrane, which suggests thatboth regions have physiclogically similar channels. Fast twitch fibers had larger INA on the endplate border and extrajunctional membrane and manifest fast and slow inactivation of INA at more negative potentials than slow twitch fibers. For normal muscle, the differences between INA on fast and slow twitch fibers might: (1) enable fast twitch fibers to operate at high firing frequencies for brief periods; and (2) enable slow twitch fibers to operate at low firing frequencies for prolonged times. Disorders of skeletal membrane excitability, such as the periodic paralyses and myotonias, may impact fast and slow twitch fibers differently due to the distinctive Na+ channel properties of each fiber type. © 1993 John Wiley & Sons, Inc. 相似文献
82.
Clanton C. Shipp Paul S. Berger Manya S. Deehr Bess Dawson-Hughes M.D. 《Calcified tissue international》1988,42(5):287-292
Summary Precision of dual-photon absorptiometry (DPA) measurements was determined in a lumbar spine phantom and in humans. Approximately
half of the measurements were made before and half after a153gadolinium source change. The phantom was measured with different amounts of acrylic, which simulates human soft tissue, in
order to evaluate the influence of body thickness on bone mineral density (BMD). Results of scans analyzed with two software
versions from Lunar Radiation Corp., the widely used 08B and a prototype 08C, are compared. DPA with a cold source significantly
overestimated BMD in the phantom in the presence of large amounts (more than 25 cm) of soft tissue equivalent with version
08B but not with the newer version 08C. Similiarly, in nine subjects, there was a significant decrease in spine BMD after
a source change when scans were analyzed with version 08B (mean difference 0.026 g/cm2,P=0.002) but not with 08C (0.01 g/cm2,P=0.234). No systematic effect of source change on femoral BMD measurements was observed. The SD of the mean difference of
two measurements of the nine subjects was 0.019 g/cm2 (1.6% of the mean value) for the spine with software version 08B and 0.024 g/cm2 (2.0%) with version 08C, 0.03 g/cm2 (3.3%) for the femur neck, 0.03 g/cm2 (4.0%) for the greater trochanter, and 0.04 g/cm2 (4.9%) for Ward's triangle region of the proximal femur. The spine phanton was scanned on two other commercial bone densitometers
in order to assess inter-instrument variation. Phantom measurements of L2-4 BMD made on two Lunar Radiation Corp model DP3
scanners which differed by 2% were 10 and 12% higher than those with a Norland Corp. model 2600 scanner. 相似文献
83.
N. Glajchen S. Thomas P. Jowell S. Epstein M.D. F. Ismail M. Fallon 《Calcified tissue international》1990,46(1):28-32
Summary The paucity of information on the effect of long-term high-dose salmon calcitonin administration on normal bone mineral metabolism
and histology prompted an investigation of the influence of high-dose synthetic calcitonin in the rat. Serum ionized calcium,
osteocalcin or BGP (bone gla protein), and immunoreactive PTH were measured serially during calcitonin administration and
bone histomorphometry analyzed at 6 weeks (after sacrifice). Daily injections of salmon calcitonin, 0.4 IU/100 g (group B)
and 2 IU/100 g (group C), resulted in significant hypocalcemia at 4 hours for both experimental groups (P<0.004). Serium iPTH was significantly higher over the study period for both groups administered calcitonin. Serum BGP levels
were significantly lower than controls during the study in group C (P<0.002) and to a lesser extent in group B (P<0.05). In group C, bone histomorphometry revealed increased resorption (onteoclast count), decreased trabecular bone volume,
and decreased double-labeled tetracycline surface (bone formation). In group B an increase in osteoclast count but no alteration
in bone formation was observed. To assess the role of PTH in the above findings, high-dose calcitonin was administered to
parathyroidectomized rats. All of the above changes in bone histomorphometry were not observed in this group of animals. In
conclusion, high doses of calcitonin promote hypocalcemia, secondary hyperparathyroidism, and osteoclastosis in the normal
rat in a dose-dependent manner with very high-dose calcitonin impairing bone formation. 相似文献
84.
国产 89SrCl2治疗肿瘤骨转移灶所致骨痛临床多中心研究 总被引:1,自引:1,他引:0
目的 验证上海科兴药业公司提供的89SrCl2 注射液治疗转移性骨肿瘤所致骨痛的疗效。方法 试验采用随机、双盲、阳性药物 (英国Amersham公司生产的Metastron)对照 ,5个中心参加验证。对 90例原发病灶诊断明确的恶性肿瘤骨转移患者进行骨痛镇痛治疗 ,其中资料完整的Ⅰ组(验证组 ) 5 9例 ,Ⅱ组 (对照组 ) 2 9例 ,余 2例患者剔除。Ⅰ组中男 30例 ,女 2 9例 ,年龄 2 5~ 80 (5 9 95±13 80 )岁 ;原发性恶性肿瘤肺癌 2 1例 ,乳腺癌 2 4例 ,前列腺癌 12例 ,胃癌、肝癌各 1例 ;治疗前骨痛评分为 6~ 12 (7 5 9± 1 5 9)。Ⅱ组中男 11例 ,女 18例 ,年龄 35~ 91(5 8 93± 14 6 0 )岁 ;原发性恶性肿瘤肺癌 10例 ,乳腺癌 12例 ,前列腺癌 6例 ,胃癌 1例 ;治疗前骨痛评分为 6~ 9(7 14± 1 4 6 )。入选患者均以 14 8MBq静脉注射给药 ,疼痛得分大于 6 ,体力状况评分平均≤ 70分 ,患者预期生存期至少大于3个月。全身99Tcm 亚甲基二膦酸盐 (MDP)骨显像示多发骨骼放射性浓聚灶 ,并经实验室及其他影像学检查证实。治疗后观察 3个月。结果 Ⅰ组镇痛有效率为 6 2 71% (37 5 9例 ) ;其中无效占 15 2 4 %(9 5 9例 ) ,好转占 2 2 0 3% (13 5 9例 ) ,显效占 5 5 93% (33 5 9例 ) ,完全缓解占 6 78% (4 5 9例 )。Ⅱ组镇 相似文献
85.
抗感染重组合异种骨对犬污染性桡骨缺损的一期植骨修复作用 总被引:5,自引:0,他引:5
目的探讨抗感染重组合异种骨(anti-infective reconstituted bone xenograft,ARBX)对犬污染性桡骨缺损的一期植骨修复的效果. 方法在重组合异种骨(reconstituted bone xenograft,RBX)基础上,结合抗生素局部缓释技术,制备具有较强抗感染能力和较高成骨作用的ARBX.取成年杂种犬8只,于双侧桡骨中上段制成15 mm节段性骨缺损,在缺损处注入5×106 CFU/ml金黄色葡萄球菌1 ml,静置15分钟后,于双侧缺损区分别植入ARBX、RBX,并用钢板固定.术后6个月对存活的6只犬进行取材,通过解剖学、X线片、组织学及细菌学检查,比较ARBX和RBX一期植骨修复犬污染性桡骨缺损的效果. 结果术后6个月,ARBX侧有5只完全修复,1只中央部3 mm缺损未修复,均无骨髓炎表现,标本细菌培养均为阴性.RBX侧有1只部分修复,5只未能修复,残留8~13 mm缺损,均有明显骨髓炎表现,标本细菌培养均为阳性. 结论 ARBX具有较高成骨活性和较强的抗菌能力,能够一期植骨修复细菌污染性骨缺损. 相似文献
86.
固生蛋白tenascin对肝细胞癌血管生成及浸润转移的影响 总被引:1,自引:0,他引:1
目的 探讨固生蛋白(tenascin ,TN)在肝细胞癌(hepatocellularcarcinoma ,HCC)中的表达和与HCC血管生成及浸润转移的关系。方法 应用免疫组织化学法检测4 2例HCC、10例肝硬化和7例正常肝组织内TN的表达情况,观察与HCC病理学特点及微血管密度(microvesseldensity ,MVD)之间的关系。结果 ①TN在HCC中的阳性表达率和强度显著高于肝硬化和正常肝脏组织( χ2 =4 15 ,P <0 0 5 ;t=2 4 73,P <0 0 5 ) ;②TN在有包膜侵犯组、病理分级Ⅲ~Ⅳ组及有转移HCC中的阳性表达率及强度明显高于无包膜侵犯组( χ2 =5 4 7,P <0 0 5 ;t=2 138,P <0 0 5 )、病理分级Ⅰ~Ⅱ级组( χ2 =6 87,P <0 0 1;t=2 4 79,P <0 0 5 )以及无转移组( χ2 =10 6 ,P <0 0 1;t=2 6 93,P <0 0 1) ;③肝癌>5cm、有包膜侵犯、有转移、病理分级Ⅲ~Ⅳ级组的MVD值明显高于肝癌≤5cm(t=2 0 36 ,P <0 0 5 )、无包膜侵犯(t =2 32 8,P <0 0 5 )、无转移(t =2 4 94 ,P <0 0 5 )及病理分级Ⅰ~Ⅱ级组(t =2 2 71,P <0 0 5 )。④TN阳性表达HCC中的MVD值明显高于TN阴性表达HCC中的MVD值(t =2 4 87,P <0 0 5 )。结论 TN在HCC组织中的表达上调与其血管生成和浸润转移有关 相似文献
87.
目的探讨低密度及氧化低密度脂蛋白对内皮细胞分泌肾上腺髓质素(ADM)的影响.方法利用培养的内皮细胞株ECV-304细胞,分别与不同浓度的低密度(50 100mg/L)、氧化低密度脂蛋白(50 100mg/L)及低密度脂蛋白(50 mg/L) 氧化低密度脂蛋白(50 mg/L)进行孵育,24 h后分别收集培养上清及细胞,用放免分析检测上清及细胞内肾上腺髓质素的含量.结果低密度脂蛋白对肾上腺髓质素的分泌无影响,而氧化型低密度脂蛋白能明显刺激ADM的分泌,二者合用的作用接近于100mg/L的OX-LDL.结论OX-LDL可能具有氧化LDL使其成为OX-LDL的作用,ADM的分泌可能是对细胞损伤的一种反应. 相似文献
88.
Christina Djokoto George Tomlinson Stephen Waldman Marc Grynpas Angela M. Cheung 《Journal of clinical densitometry》2004,7(4):448-456
Dual-energy X-ray absorptiometry (DXA) and quantitative ultrasound (QUS) are the accepted modalities for the evaluation of fracture risk in the clinical setting. However, neither method provides a direct measurement of bone mechanics. In this study, we investigated a prototype device, known as a mechanical response tissue analyzer (MRTA), which provides direct mechanical measurements of mechanical properties of bone. A total of 56 healthy volunteers (20 men and 36 women) between the ages of 18 and 83 were recruited. The MRTA was used to measure the cross-sectional bending stiffness (EI) of the ulna bone. Axial speed of sound (SOS) at the ulna bone was determined by QUS; bone mineral content (BMC) and bone mineral density (BMD) were determined by DXA. Correlations, regression analysis, and analyses of variance (ANOVAs) were used to compare the three modalities. These analyses revealed that although there are strong linear relationships among the data collected by the various technologies, the bone properties reflected by MRTA are not fully explained by DXA and QUS. We conclude that the total information conveyed by MRTA measurements is unique. Further research is needed to delineate the different qualities of bone strength that are captured by MRTA, but not by DXA or QUS. 相似文献
89.
颈椎骨折常合并有不同程度的脊髓神经功能损伤及颈椎不稳定,对颈脊髓损伤治疗的目的是恢复颈椎的生理解剖关系,重建脊柱的稳定性,防止神经组织的继发性损伤,促进神经功能的恢复,早期无痛情况下的功能康复。2000年8月至2004年8月应用前路槽式减压自体长方体髂骨植骨钛合金钢板固定治疗下颈椎骨折46例,效果满意,总结如下。1临床资料本组46例,均为男性,年龄21~62岁,平均47·3岁。受伤原因:交通事故伤26例,坠落伤20例。骨折部位:C33例,C412例,C516例,C610例,C4、C5同时骨折5例。骨折类型:垂直压缩性骨折4例,屈曲型压缩性骨折23例,过伸型压缩… 相似文献
90.
Osteoporosis in men is recognised worldwide as an important and increasing public health problem. The causes are more heterogeneous than those in women. About 50% are diagnosed as secondary cases. In some secondary forms of osteoporosis the specific diagnosis results in additional therapeutic options (e.g. androgen therapy in proven hypogonadism). The basic therapy for osteoporosis in men is no different to that in postmenopausal women, namely recommendations for counteracting modifiable risk factors, especially with regard to diet, physical exercise, and calcium and vitamin D supplementation. Concerning specific drug medications, however, even today there is still a therapeutic dilemma in male osteoporosis. While older substances (e.g. calcitonin, fluoride, alfacalcidol) are approved for both sexes, all newer medications have primarily been approved for the treatment of postmenopausal osteoporosis. Health authorities request studies in purely male populations. For new drugs, fracture data are necessary while for new substances within a class (e.g. bisphosphonates), at the very least consistent effects on bone mineral density (BMD) and bone turnover markers are requested. Due to these regulatory rules, ibandronate, teriparatide and strontium ranelate are not approved in the European Union. Some years ago, alendronate was the first bisphosphonate that was approved for the treatment of men with osteoporosis, based on consistent results from two independent male studies using a daily 10 mg dosage. Very recently risedronate was approved by the FDA and EMEA. A randomised, placebo-controlled multicentre trial of 285 male patients showed, after 2 years, a 5.8% increase in lumbar spine BMD in the risedronate 35 mg once weekly group vs 1.2% in the placebo group. In a prospective controlled study on 316 men with primary or secondary osteoporosis we found, after 12 months, a lumbar spine BMD of +4.7% vs +1.0% in controls. The number of patients with one or more new vertebral fractures was 8 in the risedronate group and 20 in the placebo group (a fracture reduction of 60%). Furthermore, we found a significantly smaller decrease in height and a steeper decrease in back pain in the risedronate group. Risedronate is the first oral bisphosphonate available for men with the more comfortable once weekly dosage. 相似文献